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Aims We present 5-year echocardiographic results of combined undersizing mitral ring annuloplasty (UMRA) and coronary
artery bypass grafting (CABG) in chronic ischaemic mitral regurgitation (CIMR).
Methods
and results
Two hundred and fifty-one patients (aged 68.4+ 8.1, 62.5%male) undergoing combined CABG and UMRA in our Insti-
tution (Cardiac Surgery, Careggi Hospital, Florence, Italy) between September 2001 and March 2007 were prospec-
tively enrolled in the study. Median follow up was 32.9 months [interquartile range (IQR) 17.5–51.6]. Fourteen
patients with significant residual mitral regurgitation (MR) needing immediate intraoperative revision (n ¼ 3) or at dis-
charge (n ¼ 11) were excluded from the study. Serial echocardiograms were performed in 220 survivors at baseline,
discharge, and annually thereafter. Additionally, 17 patients died (2 early and 15 late deaths) and were also excluded
from the study. MR remained stable at 1 year and re-increased at 3 years (P, 0.001) and 5 years (P, 0.001). Five-
year actuarial survival was 83.2+4.4. Five-year freedom from re-operation for failed repair was 78.2+4.9%. Mean
systolic and diastolic diameters decreased significantly at discharge (P ¼ 0.001 and P ¼ 0.01, respectively) and at
early follow up (P ¼ 0.004 and P ¼ 0.02) but raised at 3 years (P, 0.001) and 5 years (P, 0.001). Systolic and diastolic
sphericity indexes improved at discharge (P, 0.001) remained stable at 1 year but they re-increased at 3-year control
(P ¼ 0.006 and P ¼ 0.03, respectively) with a late raise exceeding the pre-operative value (P, 0.001). Left ventricular
reverse remodelling was observed in 44.2% of the study population with 10.3% of patients showing further left ventri-
cular dilatation. At multivariable model, end-systolic volume 145 mL, systolic sphericity index 0.7, myocardial
performance index 0.9, and wall motion score index 1.5 were predictors of recurrent MR.
Conclusion Our findings emphasize the need for improved repair technique and better patient selection to identify patients with
anticipated repair failure who could benefit more from valve replacement or other procedure directly addressing
ventricular tethering.
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Introduction
Despite of improvements in mitral reparative techniques in the
recent years,1 chronic ischaemic mitral regurgitation (CIMR) still
remains a challenging surgical problem. Combined coronary
artery bypass grafting (CABG) and annular reduction with an annu-
loplasty ring (undersized mitral ring annuloplasty, UMRA) is the
most common surgical technique employed to relieve ischaemic
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regurgitation.2 Nonetheless, conflicting data are reported in the lit-
erature about long-term effectiveness of this approach.3–7
In the present study, we present 5-year echocardiographic
results after combined UMRA and CABG in terms of recurrence
of mitral regurgitation (MR), global and local LV remodelling, and
left ventricular reverse remodelling (LVRR). We also explore
potential useful predictors of recurrence of MR following com-
bined undersized annuloplasty and coronary artery bypass.
Methods
Patients population
CIMR was defined as the combination of mild-to-severe MR with (i)
prior myocardial infarction (MI) .16 days; (ii) 75% or greater stenosis
of at least one coronary vessel; (iii) a corresponding regional wall
motion abnormality; (iv) type IIIb leaflet dysfunction following Carpen-
tier’s classification8 with or without annular dilatation.
Exclusion criteria were: (i) degenerative or other non-ischaemic
aetiology; (ii) ischaemic isolated type I or type II dysfunction;8 (iii)
additional mitral valve repair procedures; (iv) other valvular or conge-
nital heart diseases; (v) previous cardiac surgery/percutaneous trans-
luminal coronary angioplasty; (vi) atrial fibrillation or sinus rhythm
with heart rate at rest .100 b.p.m.
Two hundred and fifty-one patients undergoing combined CABG
and UMRA in our Institution (Cardiac Surgery, Careggi Hospital, Flor-
ence, Italy) between September 2001 and March 2007 were prospec-
tively enrolled in the study (Table 1). Clinical follow-up information was
obtained from all survivors through outpatient visits and phone calls
and was 100% complete. Median follow up was 32.9 months [inter-
quartile range (IQR) 17.5–51.6].
Following the World Medical Association guidelines concerning
ethical principles for medical research involving human subjects,9 the
study was approved by Institutional Ethics Board. Furthermore, all
patients gave their informed consent.
Surgery
All patients underwent associated CABG. For the purpose of this
study, complete revascularization was accomplished when, at least,
one graft was placed distal to an approximately 50% diameter narrow-
ing in each of the three major vascular system in which arterial narrow-
ing of this severity was noted in a vessel1.5 mm of diameter. It was
not considered necessary to bypass all obstructed diagonal branches of
the anterior descending or marginal branches of the circumflex coron-
ary arteries for a classification of complete revascularization. Following
this definition, 100% patients underwent complete revascularization.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 1 Peri-operative data (n 5 251)
Age (year) 68.4+8.1
Gender, M/F 155/93 (62.5/37.5)
NYHA class 3.2+0.6
CCS angina class 3.09+0.4
Euroscore
Additive 8.0 +4.3
Logistic 13.6+6.1
Hypertension 92 (36.6)
Diabetes 71 (28.62)
COPD 32 (12.7)
Chronic renal disease 26 (10.3)
Cerebral vascular disease 15 (6.0)
Peripheral vascular disease 11 (4.3)
Familiar history 101 (40.2)
Myocardial infarction
.3 months 197 (78.4)
3 months 54 (21.6)
Inferior/posterior 122 (48.6)
Anterior/septal 22 (8.8)
Lateral 49 (19.5)
Combined 58 (23.1)
Diseased coronary vessels 2.4+0.5
1 15 (6.0)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 107 (42.6)
3 129 (51.4)
Left main 38 (15.1)
Medications 197 (78.4)
Angiotensin-converting enzyme inhibitors 132 (52.6)
b-adrenergic blockers 109 (43.4)
Long-acting nitrates 185 (73.7)
Diuretics 50 (19.9)
Digitalis 33 (13.1)
Calcium antagonists
Pre-operative IABP 11 (4.3)
Surgery
Cardioplegia 218 (86.8)
Antegrade 33 (13.2)
Antegrade and retrograde
CPB time (min) 123+31
CCL time (min) 92+18
Surgical approach
Left atriotomy 207 (82.4)
Transseptal 25 (10.0)
Transseptal extended to LA roof 19 (7.6)
Ring
Carpentier classica 133 (52.9)
Physioa 118 (47.1)
Ring size (mm) 27.4+1.5
24 mm 10 (4.1)
26 mm 92 (36.6)
28 mm 112 (44.6)
30 mm
CABG 37 (14. 7)
Anastomoses/patient 2.2+1.1
Arterial graft/patient 1.07+0.1
Continuous variables are presented as mean+standard deviation; discrete
variables are presented as percentage. Abbreviations: M/F, male/female; NYHA,
New York Heart Association; CCS, Canadian Cardiovascular Society; COPD,
chronic obstructive pulmonary disease; IABP, inta-aortic balloon pump; CPB,
cardiopulmonary bypass; CCL, (aortic) cross-clamp; MR, mitral regurgitation;
CABG, coronary artery bypass grafting.
aEdwards LifeSciences, Irvine, CA, USA.
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The ring size was determined by standard measurements of the
inter-trigonal distance and anterior leaflet height. A downsizing by
two ring sizes was performed in all patients. After cardiopulmonary
bypass (CPB), a transesophageal echocardiography (TEE) was per-
formed to assess residual MR: leaflet co-aptation 0.5 cm, MR1,
and systolic MV area .2 cm2 was assessed as successful repair.
Three patients needed immediate intraoperative revision for failed
repair: all underwent mitral valve replacement and were excluded
from the study.
Echocardiographic measurements and
calculations
The clinical echocardiographic evaluation was as follows. A transthor-
acic echocardiogram (TTE) and a TEE were performed within 5 days
before surgery and serial TTE were performed at discharge and
annually thereafter. Eleven patients (4.4%) with residual MR defined
as the insufficiency 2þ following valve repair documented at dis-
charge were excluded from the study. Five-year echocardiograms
were available from 61 patients (27.7%). This patient dropout was
independent of the disease status and totally due to the different
number of patients reaching different study intervals [1 year, 187
patients (85%); 3 year, 122 (55.4%)]. Echocardiographic studies were
carried out on Acuson Sequoia imaging device equipped with a
3.5 MHz ultrasound transducer (Acuson Corporation, Mountain
View, CA, USA). Standard parasternal and apical views (long-axis,
short-axis, 2-4-5-chamber views) were employed. The reliability of
echocardiographic measurements was assessed by calculating
between-observer (I.C. and C.R.) interval of agreements of main
direct measures used in this study in a different group of 20 subjects
(10 MR).10
Mitral regurgitation
The following quantitative measurements were simultaneously
employed to grade the severity of MR and final results were averages
of measured values:11–13(i) quantitative Doppler and (ii) proximal iso-
velocity surface area (PISA). For each measurement, minimum of three
cardiac cycles were averaged. The respective thresholds for mild, mod-
erate, and severe MR were ,30, 30–59, and60 mL/beat for regur-
gitant volume (RV), ,30, 30–49, and 50% for regurgitant fraction
(RF), ,20, 20–39, and40 mm2 for effective regurgitant orifice
(ERO), respectively. In patients with no or trivial MR by colour
Doppler, RV, and RF were used as calculated, and ERO was
assumed as null.
The tenting area (TA) was measured by the area enclosed between
the annular plane and mitral leaflets from the parasternal long-axis
view at mid-systole. The distance between leaflet co-aptation and
the mitral annulus plane at early and end systole measured displace-
ment of mitral co-aptation toward the LV apex.14,15 Mitral annular
areas were obtained from mitral annular dimensions in apical long-axis,
four-chamber, and two-chamber views, using an ellipsoid
assumption.16
Recurrent MR was the insufficiency 2þ at follow-up appointments
in patients with no/trivial MR at discharge.
Global left ventricular remodelling
LV volumes and left ventricular ejection fraction (LVEF) were assessed
by the bi-apical Simpson disk method.17 According to Stellbrink et al.,
18 a decrease in LV end systolic volume .15% from baseline value was
considered LVRR. The myocardial performance index (MPI) was
measured using the method described by Tei et al.19 Sphericity
indexes were obtained at end diastole and end systole (SID and SIS,
respectively) as the volume of the left ventricle divided by the
volume of a sphere with a diameter equal to the longest axis of the
left ventricle measured in the apical view.20 The wall motion score
index (WMSI) was calculated according to a 17-segment model.21
Local left ventricular remodelling
The displacement of papillary muscles (PMs) was quantified as dis-
tances from well-defined anatomic landmarks at early and end
systole.14 Lateral and posterior displacements of anterior papillary
muscles (APMs) and posterior papillary muscles (PPMs) were
measured as distances from these fixed references. Separation
between PMs was directly measured (from body to body of PMs). In
the long-axis view, the apical displacement of the PPM was measured
as the distance between the PM head and the fixed inter-valvular
fibrosa (annular-papillary distance). The WMSI of the basal and mid-
posterior and inferior segments for the PPM and of basal and mid-
lateral and anterior segments for the APM were calculated.22
Statistical analysis
The sample size was determined by GraphPad StatMate release 2.00
(GraphPad Prism Software, Inc., San Diego, CA, USA). On the basis
of preliminary data obtained by echocardiography and was determined
on the basis of the following assumptions: Type I error of 0.05 (two-
sided), power of 80%, difference in end systolic volume between
patients with or without recurrent MR of 0.78, standard deviation of
2.4. The calculated study population was 300. However, 256 patients
were recruited to allow for possible analytic problems while proces-
sing the or other eventualities potentially leading to patient attrition.
Continuous variables are presented as mean and standard deviation
(SD), categorical variables as n/N (%), odds ratios as OR, and pertinent
95% confidence intervals as CI. The bivariate association between the
independent variables and recurrent MR was assessed by the Student’s
t-test, Mann–Whitney U test, x2 test, and Fisher exact test where
appropriate.
Echocardiographic variables over time were analysed by means of
ANOVA repeated measures followed by Tukey post hoc test and Fried-
man test, where appropriate to detect differences at different study
points (discharge vs. baseline; 1 year vs. discharge; 3 years vs.1 year,
and 5 years vs. 3 years).
Multivariable logistic regression analysis by means of a backward
stepwise algorithm (cut-off for entry 0.05, for removal 0.10) was per-
formed to select independent predictors of recurrent regurgitation.
Model assumptions (linearity and additivity assumptions) were
checked by piecewise cubic polynomials (spiline functions) and
pooled interaction test,23 respectively, and found to be satisfied.
Goodness of fit of the final logistic regression models was assessed
with the Hosmer–Lemeshow statistic24 and predictive accuracy was
assessed by the concordance (c) index.23 Internal validation of predic-
tors generated by multivariable logistic regression was performed by
means of bootstrapping techniques, with 1000 cycles and generation
of OR and bias corrected 95% CI.23
Optimal cut-off values were determined as the rounding cut-off that
gives the maximum sum of sensitivity and specificity. This value should
be the shoulder at the top left of the receiver operating characteristic
(ROC) curve. Bootstrapping techniques were employed to validate the
results. Cumulative probability for death and re-operation were esti-
mated by use of the Kaplan–Meier method.
SPSS 12.0 (SPSS, Chicago, IL, USA) and Stats Direct 2.5.7
(StatsDirect, Sale, UK) were used for these calculations. Significance
for hypothesis testing was set at the 0.05 two-tailed level.
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Results
Overall survival
Early (30-day) mortality was 0.8% (n ¼ 2, respiratory failure and
low-output syndrome). During the follow-up 15 patients died:
six of cardiac causes [heart failure (n ¼ 3; 36, 45, and 54
months), myocardial infarction (n ¼ 2; 31 and 42 months), and
arrhythmia (n ¼ 1; 59 months)], eight of non-cardiac causes [multi-
organ failure (n ¼ 1; 6 months), respiratory failure (n ¼ 1; 14
months), infection (n ¼ 2; 3 and 8 months), stroke (n ¼ 2; 12
and 43 months), and malignancy (n ¼ 2; 55 and 59 months)] and
1 of sudden, unexplained death (22 months). Five-year actuarial
survival was 83.2+ 4.4 (Figure 1).
Residual and recurrent mitral
regurgitation
Among 220 patients surviving CABG and reductive annuloplasty
(Figure 2), mean MR remained stable at 1 year and re-increased at
3-year (P, 0.001) and 5-year studies (P, 0.001, Table 2). At
5-year echocardiography, 17 patients (27.8%) had no/trivial recur-
rent MR, 17 (27.8%) had MR 2þ, 19 (31.1%) 3þ, and 8 (13.1%)
4þ(Figure 3). Seventeen patients underwent re-operation for
failed repair due to recurrent MR: four (3.7%) had a re-MV repair
and 13 (12.1%) underwent mitral valve replacement. Freedom
from re-operation for failed repair was 78.2+4.9% (Figure 4).
Global left ventricular remodelling and
left ventricular reverse remodelling
Ventricular diameters and left atrial dimensions reduced signifi-
cantly at discharge (P, 0.001, P ¼ 0.005, P ¼ 0.002, respectively),
showing no further significant change at subsequent controls
(Table 3). Mean ESV and EDV decreased significantly at discharge
(P ¼ 0.001 and P ¼ 0.01, respectively) and at early follow up
(P ¼ 0.004 and P ¼ 0.02), but re-increased at 3-year (P, 0.001)
and 5-year (P, 0.001) studies. Furthermore, ejection fraction
and MPI did not show significant changes over time. Systolic and
diastolic sphericity indexes improved at discharge (P, 0.001),
remained stable at 1-year (P ¼ ns) but they increased at 3-year
control (P ¼ 0.006 and P ¼ 0.03 for SIS and SID, respectively)
with a late increase exceeding the pre-operative value (P,
0.001). Finally, WMSI reduced significantly at discharge, remained
constant at 1 year, but re-increased at 3-year (P ¼ 0.02) and
5-year (P, 0.001) echocardiograms. Sixty percent of patients
(n ¼ 132) showed reverse remodelling at discharge and percent
of patients showing LVRR increased significantly at 1-year (P,
0.001), but it reduced at 3-year (P, 0.001) and 5-year (P ¼
0.01) studies (Figure 5).
Local left ventricular remodelling
For local remodelling (Table 4), indexes of posterior and lateral dis-
placement of both PMs, PM separation, PPM fibrosa, and WMSIs
were reduced significantly at discharge and remained constant at
1 year; nevertheless, PPM posterior (3 years, P ¼ 0.01; 5 years,
P ¼ 0.02), PPM lateral (3 years, P ¼ 0.008; 5 years, P ¼ 0.02),
PMs separation (3 years, P, 0.001; 5 years, P ¼ 0.02) and PPMs
fibrosa (P, 0.001) re-increased significantly at subsequent
Figure 1 Five-year survival and 95% confidence interval
(dotted lines) following undersized mitral ring annuloplasty and
coronary artery bypass grafting in patients with ischaemic mitral
regurgitation
Figure 2 Patients selection. Abbreviations: UMRA, undersized
mitral ring annuloplasty; CABG, coronary artery bypass grafting;
MR, mitral regurgitation. See text for definitions
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controls. In contrast, lateral and posterior displacements of the
APM as well as WMSIs did not show further significant changes.
Predictors of recurrent mitral
regurgitation
The unadjusted relationship between recurrent MR and indepen-
dent variables are shown in Table 5. Multivariable logistic
regression analysis identified systolic sphericity index (OR ¼ 4.97,
95% CI ¼ 2.11–6.40, P, 0.001), myocardial performance index
(OR ¼ 4.66, 95% CI¼2.01–5.43, P, 0.001), end systolic volume
(OR¼2.59, 95% CI ¼ 1.19–3.77, P ¼ 0.003), and wall motion
score index (OR ¼ 1.99, 95% CI ¼ 0.88–2.37, P ¼ 0.04) as inde-
pendent predictors of the occurrence of recurrent MR internal
validation of such multivariable analysis by means of bootsrapping,
including the same variables of standard logistic regression model,
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Table 2 Mitral regurgitation
Baseline, n 5 220 Discharge, n5 220 1 year, n5 187 3 years, n5 122 5 years, n5 61 *P
MR 3.1+ 0.6 0.3+ 0.5* 0.3+0.6 1.2+0.7† 2.1+1.2‡ 0.001
Direction of regurgitant jet
Central 70 (31.8) – – – –
Anterior 28 (12.7) – – – –
Posterior 54 (24.6) – – – –
Complex 68 (30.9) – – – –
Carpentier’s classification
Type IIIb 134 (60.9) – – – –
Type IIIbþannular dilatation 86 (39.1) – – – –
Quantitative data
TA 3.4+1.1 1.9+0.5* 1.9+0.5 2.1+0.6† 2.4+0.7‡ ,0.001
ERO 36+11 – – – 19+11‡ –
RF 45+10 – – – 26+14‡ –
RV 56 +13 – – – 29+16‡ –
CH 1.2+0.3 0.8+0.2‡ 0.8+0.2 0.9+0.3 0.9+0.3 0.02
MAs 4.1 +1.2 2.6+0.7* 2.6+0.4 2.6+0.7 2.6+0.7 0.001
MAd 5.0 +1.1 3.3+0.5* 3.4+0.6 3.4+0.9 3.4+0.9 ,0.001
MDp – 2.3+0.5 2.4+0.3 2.3+0.3 2.3+0.3 0.2
Continuous variables are presented as mean+standard deviation. Discrete data are presented as n (%). P ¼ ANOVA over time significance. MR, mitral regurgitation; TA, tenting
area (cm2); ERO, effective regurgitant orifice (mm2); RF, regurgitant fraction (%); RV, regurgitant volume (mL); CH, co-aptation height (cm); MAs, (systolic) mitral annular area
(cm2); MAd, (diastolic) mitral annular area (cm
2); MDP, Trans mitral diastolic gradient (mmHg).
*Significance vs. pre-operative (see text).
†One year (see text).
‡Three years (see text).
Figure 3 Mitral regurgitation (%) at different echocardio-
graphic controls (P, 001)
Figure 4 Five-year freedom from re-operation for recurrent
ischaemic mitral regurgitation (dotted lines, 95% confidence
interval)
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further confirmed the significant predictive of recurrent MR (boot-
strap OR ¼ 2.3, 95% bias-corrected 95% CI ¼ 1.1–5.2). Finally,
logistic regression model was reliable (Hosmer–Lemeshow test,
P ¼ 0.7) and accurate (c-index ¼ 0.81).
ROC analysis showed that SIS had 100% of sensitivity and speci-
ficity with an optimal cut-off 0.7 (95% CI by bootstrapping 0.58–
0.81) (area under curve 1; 95% CI 0.70–1; P, 0.001).
MPI with a cut-off 0.9 (95% CI by bootstrapping 0.75–0.96)
had 85% of sensitivity and 84% of specificity (area under curve
0.94; 95% CI 0.67–1; P, 0.001). In addition, ESV 145 mL
(95% CI by bootstrapping 134–155) had 90% of sensitivity and
specificity (area under curve 0.87; 95% CI 0.80–0.94; P, 0.001).
Finally, WMSI 1.5 (95% CI by bootstrapping 1.35–1.62) had
80% of sensitivity and 82% of specificity (area under curve 0.81;
95% CI 0.77–0.91; P ¼ 0.002).
Discussion
An established therapeutic approach to relieve CIMR, in associ-
ation with CABG, is an undersized mitral ring annuloplasty
(UMRA)2 which, by reducing the septal– lateral dimensions and
the valve area, brings both mitral leaflets into apposition. Nonethe-
less, after encouraging initial results,25 different studies have
revealed a significant proportion of patients developing recurrent
MR during follow-up4,7,26 which has been mainly related to contin-
ued LV remodelling and persistent leaflet tethering.5,27 We
reported our experience with this technique. Patients were fol-
lowed up by serial TTE over a 5-year period and recurrence of
MR, local, and global LV remodelling, and LV reverse remodelling
were explored. We also identified potential useful predictors of
MR-recurrence following combined UMRA and CABG.
Because of unavailable complete echocardiographic data,
15 patients who died late after surgery were excluded from the study.
Recurrence of mitral regurgitation
In our report, recurrent MR significantly increased at 3-year and
5-year controls with and 27.8% of patients showing mild,
31.1%moderate, and 13.1% severe MR at latest follow-up. Five-year
freedom from re-operation for failed repair was 78.2+4.9%. Hung
et al.5 showed 72% of patients with moderate/severe MR at late
control (47+27 months) after ring annuloplasty and CABG.
Accordingly, Tahta et al.26 in a large single-centre surgical series
reported a 29% incidence of MR 2 over a 3-year follow-up
period. However, in these studies, annuloplasty had not been rou-
tinely performed in a restrictive fashion. In contrast with these
results, Braun and coworkers4 reported that, in 87 patients under-
going restrictive ring annuloplasty (2 ring sizes, median ring size
26), no patient showing MR 3 and 2 with MR graded 2þ at
18-month follow-up. In addition, Geidel et al.28 reported that
15 of 29 patients having no MR (52%), nine patients with
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Global left ventricular remodelling
Baseline Discharge 1 year 3 years 5 years P
EDD 62+7 54+7* 55+7 53+7 54+7 0.03
ESD 52+8 44+6* 43+6 42+6 43+6 0.04
LA 50+7 45+3* 46+3 46+3 46+4 0.053
ESV 150+24 114+15* 108+16† 121+11‡ 136+11§ ,0.001
EDV 195+35 164+26* 156+19† 171+23‡ 191+23§ 0.02
LVEF 30+12 31+10 30 +10 30 +11 29 +12 0.38
MPI 0.79+0.2 0.76 +0.1 0.75+0.1 0.75+0.1 0.76+0.1 0.2
SIS 0.65+0.2 0.50+0.1* 0.50+0.1 0.58+0.1
‡ 0.66+0.2§ 0.03
SID 0.72+0.1 0.62+0.1* 0.60+0.1 0.66+0.1
‡ 0.74+0.1§ 0.01
WMSI 1.4+0.7 1.2+0.3* 1.1+0.2 1.3+0.4‡ 1.5+0.5§ 0.006
Continuous variables are presented as mean+standard deviation. P ¼ ANOVA over time significance. EDD, (left ventricular) end diastolic diameter (mm); ESD, (left ventricular)
end systolic diameter (mm); LA, left atrium (mm); ESV, (left ventricular) end systolic volume (mL); EDV, (left ventricular) end diastolic volume (mL); LVEF, Left ventricular ejection
fraction (%); MPI, myocardial performance index; SIS, systolic sphericity index; SID, diastolic sphericity index; WMSI, wall motion score index.
*Significance vs. pre-operative (see text).
†Discharge (see text).
‡One year (see text).
§Three years (see text).
Figure 5 Left ventricular reverse remodelling (P ¼ 0.02)
S. Gelsomino et al236
 at U
N
IV
ERSITA
 D
EG
LI STU
D
I D
I FIREN
ZE, BIBLIO
TECA
 BIO
M
ED
ICA
 on M
arch 19, 2012
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
MR1þ (31%), and five patients with MR2þ (17%), 13+7 months
after mitral annuloplasty and CABG. Of interest, they performed
mitral downsizing in a ‘dynamic fashion’ dependent on LV function
(2, 3, or4 ring sizes for LVEF.30, 20–30%, 20%, respectively).
Left ventricular remodelling
In our experience, we observed a significant global remodelling late
after reductive annuloplasty: LV volumes increased significantly and
WMSI exceeded its pre-operative value. Furthermore, LV became
more spherical with sphericity indexes exceeding their baseline
values at 5-year echocardiography. Regarding local remodelling,
we observed a late ‘asymmetric’ lateral and posterior displacement
of PPM with APM displacement which remained constant over time.
Of interest, WMSI of the segments underlying both PMs, after a
transient reduction, were relatively stable and these data suggest
that the late PPM displacement seems to be due to the continued
global remodelling, rather than local remodelling in this area.
Left ventricular reverse remodelling
According to Stellbrink et al., 18 we considered a decrease in LV
end systolic volume .15% from baseline value as LVRR. In this
fashion LVRR was observed, at late control, in 44.2% of patients
with 10.3% showing further increment in ESV. Braun and co-
workers6 reported 60.5% of patients with significant reverse LV
remodelling18 months after restrictive mitral annuloplasty. We
had comparable results at 12-month follow-up (77.5%) but LVRR
dramatically worsened at late controls. However, our data are not
comparable because this group considered a 10% reduction in
EDD as significant LVRR; however, measurements of LV volumes
have been demonstrated to be more reliable than LV diameters in
assessing LV remodelling, especially in enlarged ventricles.29
Predictors of recurrent mitral
regurgitation
At multivariable model, ESV  145 mL, SIS  0.7, MPI  0.9, and
WMSI  1.5 were predictors of recurrent MR. These results
emphasize the importance of the extent of pre-operative LV
global remodelling as having a central role in predicting inadequate
results after UMRA. A new finding in this study is that MPI predicts
the likelihood of MR, whereas LVEF was not significant. The MPI is
a combined systolic and diastolic Doppler-derived index for the
assessment of global LV performance which, differently from
LVEF, is independent of LV loading conditions and heart rate.
Study limitation
Our study findings should be viewed in light of some inherent
limitations.
1. Evaluation of LVRR was based on volumes obtained by echocar-
diography; volumetry by 2D echocardiography depends on geo-
metric assumptions and is subject to image-plane positioning
errors. Hence, it is not accurate in left ventricles that are dis-
torted in shape such as after myocardial infarction. However,
this limitation belongs to most of published paper regarding
this pathology.
2. Viability testing was not performed in these patients. Therefore,
lack of LVRR in non-responders might be also due to irrevers-
ible ischaemic myocardial damage (not viable myocardium).
This issue deserves further investigation.
3. Postoperative evaluation of the coronary status was not
assessed. It would have been helpful to differentiate between
surgical failure (valve repair and CABG) and the progress of
the coronary disease.
4. Fifteen patients with late deaths were not included in the study.
They could have benefited from serial echocardiograms possibly
with different results.
5. Estimated cut-offs are known to be very susceptible to changes
in the study population. We employed bootstrapping tech-
niques to validate the results, nonetheless, it has also been
documented that the sensitivity/specificity associated with
these cut-offs are overly optimistic.
Strength of the study
As far as we know, this is the largest cohort reported with UMRA
in CIMR patients with detailed echocardiographic follow-up.
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Table 4 Local left ventricular remodelling
Baseline Discharge 1 year 3 years 5 years P
PPM posterior D 2.6 +0.6 2.2+0.5* 2.1+0.3 2.3+0.3† 2.5+0.6‡ 0.02
APM posterior D 2.9+0.5 2.5+0.2* 2.4+0.3 2.4+0.3 2.4+0.3 ,0.001
PPM lateral D 2.0+0.4 1.6+0.3* 1.6+0.3 1.8+0.3† 2.1+0.3‡ 0.01
APM lateral D 1.3+0.3 1.0+0.2* 1.1+0.3 1.1+0.3 1.1+0.3 0.008
PMs separation 3.6+0.5 3.2+0.2* 3.0+0.2 3.3+0.2
† 3.5+0.4‡ ,0.001
PPM-fibrosa D 6.7+0.6 6.0+0.4* 6.0+0.4 6.4+0.4† 6.6+0.5‡ 0.02
PPM WMSI 2.2+0.2 2.0+0.2* 2.1+0.2 2.1+0.2 2.1+0.2 0.03
APM WMSI 1.3+0.4 1.0+0.1* 1.0+0.1 1.1+0.1 1.1+0.1 0.003
Continuous variables are presented as mean+standard deviation. P ¼ ANOVA over time significance. D, distance (cm); PPM, posterior papillary muscle; APM, anterior papillary
muscle; PMs, papillary muscles; WMSI, wall motion score index.
*Significance vs. pre-operative (see text).
†One year (see text).
‡Three years (see text).
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Furthermore, our patient cohort was more homogeneous than in
other study:30 All patients underwent associated CABG, they had
no concomitant MV procedures, and the entire cohort was
uniform regarding the MV ischaemic leaflet dysfunction. Moreover,
to assess results for MV repair, we studied true ‘recurrent’.
MR excluding those patients with ‘residual ‘MR in whom the
insufficiency was presumably never eliminated at surgery. Addition-
ally, we undertook valve sizing in a standardized fashion and the
degree of undersizing was homogeneous over the 5-year-period
of the study. Finally, we used only two rings (Carpentier’s rigid
or semi-flexible rings).
Clinical implications
In our experience, UMRA does not ensure successful and durable
elimination of MR in all patients. Those who can benefit from com-
bined UMRA and CABG should be pre-operatively identified utiliz-
ing echo predictors of recurrent MR. However, restrictive
annuloplasty resulted to be ineffective in a large percentage of
patients and results of this study suggest the need for different
approaches directly addressing ventricular tethering in most of
CIMR patients.31–34 Such procedures may include LV plasty with
volume reduction, chordal elongation or cutting, PM displacement,
and leaflet elongation techniques as well as cardiac the employ-
ment of support devices introduced in recent years in clinical prac-
tice.35,36 Mitral valve replacement, largely employed in the past in
ischaemic regurgitation, although eliminates the short-term risk
of recurrent MR, it is associated with poor long-term survival.37
Thus, in our actual policy, we do not consider MV replacement
as a reasonable alternative to repair.
Conclusions
Combined UMRA and CABG provided poor mid-term results with
significant recurrent MR. Our findings emphasize the need for
improved repair technique and better patient selection to identify
patients with anticipated repair failure who could benefit more
from valve replacement or other procedure directly addressing
ventricular tethering. Long-term prospective studies on this con-
troversial issue are encouraged.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Bivariate relationship of independent variables
with recurrent mitral regurgitation
MR1 MR2 P
Age 69.2+6.4 67.8+8.3 0.25
Male gender 98 (62.1) 38 (65.5) 0.9
NYHA class 3.2+0.5 3.2+0.5 0.74
CCS angina class 3.0+0.3 3.1+0.3 0.32
Euroscore
Additive 7.9+3.5 8.1+4.6 0.66
Logistic 12.9+6.3 12.8+5.5 0.88
Hypertension 63 (39.9) 25 (40.3) .0.9
Diabetes 51 (32.2) 17 (21.4) 0.49
COPD 21 (13.2) 7 (11.2) 0.71
Chronic renal disease 20 (12.6) 4 (6.5) 0.18
Cerebral vascular
disease
10 (6.4) 4 (6.5) 0.9
Peripheral vascular
disease
8 (5.1) 2 (3.3) 0.6
Familiar history 67 (42.4) 31 (50.0) 0.31
MI posterior/inferior 79 (50.0) 28 (45.1) 0.6
Grade of MR 3.0+0.4 3.1+0.4 0.1
Central direction of
regurgitant jet
49 (31.0) 21 (33.8) 0.8
Annular dilatation 66 (41.7) 20 (32.2) 0.19
TA 3.3+1.1 3.6+1.2 0.06
ERO 38.3+13 36.1+11 0.09
RF 45.6+11 44.7+12 0.61
RV 57.4+13 55.0+10 0.25
CH 1.3+0.2 1.1+0.1 0.004
MAs 4.1+1.2 4.3 +1.2 0.3
MAd 4.9+1.2 5.2+1.2 0.11
Number of diseased
coronary vessels
2.5 +0.4 2.4+0.4 0.11
Left main coronary
artery
28 (17.7) 8 (12.9) 0.3
Pre-operative IABP 6 (3.7) 2 (3.2) 0.88
Ring size 27.6+0.5 27.3+0.9 0.21
Anastomoses/patient 2.2 +1.2 2.1+1.0 0.51
Arterial Graft/patient 1.09 +0.1 1.06 +0.1 0.43
CCL time 124.4+30 123.28 0.8
CPB time 92.7+16 90.7 +18 0.61
EDD 65.1 +4 60.6+5 0.003
ESD 53.9+4 51.3+3 0.01
LA dimensions 49.2+7 50.3+7 0.66
ESV 164.7+23.9 131.2+19.8 ,0.001
EDV 215.3+38.1 194.1+39.2 0.09
LVEF 24.4+7 34.1+6 ,0.001
MPI 0.90+0.15 0.69+0.17 ,0.001
SIS 0.74+0.1 0.54+0.1 ,0.001
SID 0.80+0.1 0.64+0.09 0.002
WMSI 1.6+0.2 1.1+0.1 ,0.001
PPM posterior D 2.4 +0.4 2.6 +0.5 0.2
APM posterior D 2.7+04 2.9+0.5 0.08
PPM lateral D 1.9+0.4 2.0+0.4 0.59
APM lateral D 1.3+0.3 1.1+0.2 0.008
PMs separation 3.6 +0.5 3.6 +0.4 0.74
PPM fibrosa D 6.7+0.6 6.6+0.5 0.25
PPM WMSI 2.0+0.1 2.2+0.2 0.069
APM WMSI 1.3+0.4 1.1+0.3 0.04
MRþ(2), presence (absence) of recurrent mitral regurgitation; NYHA, New York
Heart Association; CCS, Canadian Cardiovascular Society; COPD, chronic
obstructive pulmonary disease; MI, myocardial infarction; MR, mitral regurgitation;
MR, mitral regurgitation; CABG, coronary artery bypass grafting; TA, tenting area;
ERO, effective regurgitant orifice; RF, regurgitant fraction; RV, regurgitant volume;
CH, co-aptation heigh; MAs, systolic mitral annular area; MAd, diastolic mitral
annular area; IABP, inta-aortic balloon pump; CPB, cardiopulmonary bypass; CCL,
(aortic) cross-clamp; EDD, end diastolic diameter; ESD, end systolic diameter; LA,
left atrium); ESV, end systolic volume; EDV, end diastolic volume; LVEF, left
ventricular ejection fraction; MPI, myocardial performance index; SIS, systolic
sphericity index; SID, diastolic sphericity index; WMSI, wall motion score index; D,
distance; PPM, posterior papillary muscle; APM, anterior papillary muscle; PMs,
papillary muscles.
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